← Back to home

SEVERE RAPIDLY PROGRESSIVE INTERSTITIAL LUNG DISEASE ASSOCIATED WITH ANTI-MDA5

Clinical trials for SEVERE RAPIDLY PROGRESSIVE INTERSTITIAL LUNG DISEASE ASSOCIATED WITH ANTI-MDA5 explained in plain language.

Never miss a new study

Get alerted when new SEVERE RAPIDLY PROGRESSIVE INTERSTITIAL LUNG DISEASE ASSOCIATED WITH ANTI-MDA5 trials appear

Sign up with your email to follow new studies for SEVERE RAPIDLY PROGRESSIVE INTERSTITIAL LUNG DISEASE ASSOCIATED WITH ANTI-MDA5, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Not yet recruiting 1

Promising drug could save lives in rare, deadly lung disease

Disease control Not yet recruiting

This study tests a drug called teclistamab in 24 adults with a severe, rapidly worsening lung disease linked to anti-MDA5 antibodies. The disease has a very poor outlook, with only about 25% of patients surviving 90 days without a lung transplant. Teclistamab aims to improve surv…

Matched conditions: SEVERE RAPIDLY PROGRESSIVE INTERSTITIAL LUNG DISEASE ASSOCIATED WITH ANTI-MDA5

Phase: PHASE2 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control

Last updated Jun 18, 2026 11:49 UTC

SEVERE RAPIDLY PROGRESSIVE INTERSTITIAL LUNG DISEASE ASSOCIATED WITH ANTI-MDA5

Get alerted when new SEVERE RAPIDLY PROGRESSIVE INTERSTITIAL LUNG DISEASE ASSOCIATED WITH ANTI-MDA5 trials appear

Promising drug could save lives in rare, deadly lung disease